Navigation Links
Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
Date:11/9/2008

is a recombinant adeno-associated viral (rAAV) vector that transfers the SERCA2a gene into heart muscle cells. MYDICAR is delivered in a single dose directly to the heart muscle during a short outpatient procedure, performed in a standard cardiac catheterization laboratory via a small incision in the upper leg.

"These data demonstrate the safety of MYDICAR, and the improvements in cardiac function and overall condition observed in some patients further validate our target and approach," said Krisztina M. Zsebo, Ph.D., Chief Executive Officer of Celladon. "Given these early encouraging results, we are excited to have been given clearance to move into phase 2 of our study to continue to evaluate the ability of MYDICAR to improve heart function in more patients."

CUPID, which is funded by Celladon, is a Phase 1/2 trial. The Phase 1 portion reported today is an open-label, sequential dose escalation study. The Phase 2 portion is a randomized, double-blind, placebo-controlled, parallel-group, dose ranging trial that compares the use of MYDICAR at two or three dose levels with placebo. CUPID is expected to enroll 46 patients with advanced heart failure at 15 U.S. medical centers.

Study Results

Data from the Phase I in advanced heart failure was presented, and demonstrated that MYDICAR had an acceptable safety profile in these first nine patients, as determined by study investigators and an independent safety committee. In addition, improvements from baseline to six months across a number of parameters important in assessing heart failure status were observed, including symptomatic (5 patients), functional (4 patients), biomarker (2 patients) and left ventricular function/remodeling (6 patients). Of the nine patients treated, two with low levels of pre-existing antibodies to the AAV vector did not show improvement in these parameters.

The data are consistent with safety established for other rAAV vectors, which has been demonstrated in cl
'/>"/>

SOURCE Celladon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
2. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
3. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
4. NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
5. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
6. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
7. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
10. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
11. Lutonix Inc. Announces $20 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- TODAY, AEGATE, the leader in medicine ... appointment of Peter Fox as Chief Technology ... Partner Officer. Peter has served as Development ... by Oracle in 2011. Prior to Datanomic, ... and subsequently Convergys, a world renowned billing system ...
(Date:12/19/2014)... Pa. , Dec. 19, 2014 You,re ... routine checkup and cleaning when he or she says ... you,ve probably heard before, you may have several questions ... You,ll be relieved to know it,s nothing to worry ... answer patients, questions and alleviate any anxiety the public ...
(Date:12/19/2014)... Dec. 19, 2014 Breckenridge Pharmaceutical, Inc. announced ... with MSN Laboratories Pvt. Ltd. ( Hyderabad, India ... commercialize several new ANDAs.  Under the terms of the ... exclusively to Breckenridge for the U.S. market, and Breckenridge ... Breckenridge and MSN have agreed to develop an oral ...
Breaking Medicine Technology:Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Root Canals Have Become More Routine 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2
... American Medical Systems® (AMS) (Nasdaq: ... and therapies for male and female pelvic health, today ... Program (STEP) in Europe. The program is designed to ... about solutions for the treatment of erectile dysfunction (ED) ...
... CHICAGO, Jan. 14, 2011   The Cleveland Clinic and ... support the Clinic,s effort to become a clinically integrated ... together the Cleveland Clinic Hospitals, physicians, and more than ... Cleveland Clinic, through its Community Physician Partnership (CPP), recognized ...
Cached Medicine Technology:American Medical Systems Launches STEP Patient Education Program in Europe 2American Medical Systems Launches STEP Patient Education Program in Europe 3Valence Health Selected by Cleveland Clinic to Support Clinical Integration Program 2
(Date:12/21/2014)... December 21, 2014 AlignLife of Norton ... need while at the same time helping people get their ... non-profit community-based organization committed to serving those persons in Muskegon ... needs to improve the quality of life. Dr. Michael Rykse ... impact in the local community and he knew he found ...
(Date:12/21/2014)... December 21, 2014 Serious Buyer, Andrew ... 1967 Jm Morrison and the Doors International Ballroom at ... would also be the only time that Morrison's mother ... on Nov. 25, 1967. According to Hawley, “This would ... did play the Alexandria Roller Rink earlier that year ...
(Date:12/21/2014)... Parker & Sons, Inc. a market leader ... other similar home contractor services announces a record number ... expert contracting services. The company is considered by many ... Arizona for well over 40 years. Parker and Sons ... quality customer service to the residents and business owners ...
(Date:12/21/2014)... Over the past 39 years, NES ... of emergency departments across the nation, from quality of ... translated into an innovative suite of tools, systems, and ... enhance the patient experience. , NES Health, a ... management services for hospitals, announced the development and launch ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 SCI ... of the issues and systemic barriers for disabled athletes ... Paratriathlon Champion. Scheidies has a condition called juvenile macular ... He describes how he adapted his athletic ambitions to ... his success in triathlon to pioneer the way for ...
Breaking Medicine News(10 mins):Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 2Health News:Parker & Sons Announces Record Number Of Favorable Reviews In 2014 With Regard To Its Expert Contracting Services 3Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3
... Highlights Influenza Virus Research at Drexel University*PHILADELPHIA, May 1 ... demonstrated the importance of natural killer, or NK, cells ... may help us understand how the body,s immune system ... no studies have been conducted on the specific H1N1 ...
... Van Andel Research Institute (VARI) Research Scientist ... Award for research submitted for presentation at the American ... , Chen, a researcher in VARI,s Laboratory of ... the meeting held in Denver from April 18-22, where ...
... Boston, Mass. - A new paper published in the ... of Medical Internet Research evaluates consumers, experiences with ... a system developed by researchers in the Children,s Hospital ... has been adapted by PCHR providers including Dossia, Microsoft ...
... crisis improved long-term outcomes, study found , , FRIDAY, May ... drug during a coronary emergency can save lives and ... , The one-year risk of death or major heart ... episodes of acute coronary syndrome who received the drugs, ...
... Tech Rapid Alert System Enables Hospitals to Rapidly Notify Staff, Community ... ... Clark, New Jersey, May 1, 2009 -- Mobile Health Tech, the ... 2.0 of its Hospital Rapid Notification Alert System™. This new release ...
... SignatureForum, a leading online consumer advocacy group, has ... family of skin care and anti-aging websites, ... the Chicago cosmetic market, New Image Specialists, growing popularity ... encompassing a network of more than 300 medical spas ...
Cached Medicine News:Health News:Natural Killer Cells May Help Protect Against New Strains of Influenza Virus 2Health News:Natural Killer Cells May Help Protect Against New Strains of Influenza Virus 3Health News:VARI researcher chosen for highly competitive Scholar-in-Training Award 2Health News:New study evaluates community response to personally controlled health information 2Health News:New study evaluates community response to personally controlled health information 3Health News:Cholesterol Drugs May Help in Cardiac Emergency 2Health News:Hospital Rapid Alert System Supports Swine Flu Pandemic Communications 2Health News:SignatureForum Introduces NewImageSpecialists.com 2
New!...
...
Mendez Multi-Purpose LASIK Forceps. To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps, Titanium...
The CGPL capsulotomy contact glass was designed by Riquin, Fankhauser et al. for the dissection of opacified posterior lens capsules and membranes in the pupillary and retropupillary space with the Y...
Medicine Products: